zurück Home

Ösophagus - Karzinom: Studien

preoperative Radiochemotherapie besser als nur OP

Die Radiochemotherapie mit FOLFOX(Carboplatin-5-FU-Leukovorin) erzielt beim inoperablen Ösophaguskarzinom ein gleich gutes progressionsfreies Überleben wie mit Cisplatin-5-FU.

Radiochemotherapie mit 50,4 Gy v. 64,8Gy. Chemotherapie mit Carboplatin, 5-FU und Paclitaxel. 11 therapiebedingte Todesfälle bei 64,8Gy, 2 Todesfälle bei 50,4Gy

A phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer.

Phase II randomized trial of two nonoperative regimens (A,B) of induction chemo followed by ChemoRT with localized carcinoma of the esophagus

Phase III trial of combined modality therapy for esophageal cancer: high-dose (A) vs. Standard-dose RT (B)

Radiochemotherapie: 27% 5a-survival. Nur Radiotherapie: 0% 5a-survival.

Definitive radiochemotherapy with 5-FU / cisplatin plus/minus cetuximab in unresectable locally advanced esophageal cancer: a phase II study. Offene Studie, Studienleiter: Dirk Rades

Beim operablen Ösophaguskarzinom erzielt die präoperative FOLFOX-Chemotherapie bessere Behandungsergebnisse als die Radiochemotherapie (CROSS-Protokol).

Panitumumab

Im Stadium I und II des Ösophaguskarzinoms verbessert die praeoperativer Radiochemotherapie das Gesamtüberleben und die Rate der Ro-Resektionen nicht, erhöht aber die perioperative Mortalität.

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer

Teil von

1.) Cooper JS, Guo MD, Herskovic A et al.:
Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective trial (RTOG 85-01). Radiation Therapy Oncology Group.
JAMA 281(1999):1623-7

2.) Minsky B, Neuberg D, Kelsen DP et al.:
Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus.
IJROBP 43(1999):517-23.

3.) Bedenne L, et al.:
Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.
JCO 25(2007):1160-8.

4.) Cunningham D, et al.:
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
NEJM 355(2006):11-20.

5.) Burmeister BH, et al.:
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.
Lancet Oncol 6(2005):659-68.

6.) Tepper J, et al.:
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
JCO 26(2008):1086-92

7.) Lee JL, et al.:
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.
Ann Oncol 15(2004):947-54

8.) Ychou M, et al.:
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
JCO 29(2011):1715-21

9.) Stahl M, et al.:
Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.
JCO 27(2009):851-6.

10.) Minsky BD, et al.:
INT 0123 (Radiation Therapy Oncology Group 94–05) Phase III trial of combined-modality therapy for esophageal cancer: high-dose vs. standard-dose radiation therapy.
J Clin Oncol 20(2002):1167–1174

11.) Yang H, Liu H, Chen Y, et al.:
AME Thoracic Surgery Collaborative Group. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
J Clin Oncol 2018
doi:10.1200/JCO.2018 [Epub ahead of print]

12.) Hulshof M, et al.:
Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study).
J Clin Oncol 2021;39:2816-2824